Equity research analysts tracking ENDRA Life Sciences Inc. (NASDAQ: NDRA) issue long-term price targets and forecasts that reflect high speculative upside potential relative to its micro-cap valuation. Projections from firms covering the medical technology developer focus heavily on upcoming clinical milestone progress, regulatory approvals for its non-invasive liver ultrasound technologies, and cash runway management, though analysts consistently warn that the stock carries extreme speculative risk.